Azad Engineering has delivered one of the most striking stock market stories of 2026. The shares have surged 111% in six months to around ₹2,964, driven by a simple but powerful narrative: deepening integration with GE Vernova and a breakthrough in defense manufacturing. Yet beneath this rally lies a complex story about revenue volatility, working capital dynamics, and the delicate balance between capacity creation and execution. The company's order book stands at approximately ₹6,500 crores, which is 11-12x FY26 revenue, providing exceptional forward visibility. But visibility isn't the same as certainty, and the market is pricing in near-perfect execution from here. Transcripts
The company's relationship with GE Vernova has evolved from supplier to strategic partner.
In April 2026, they inaugurated a 7,600 sq meter state-of-the-art facility for Baker Hughes, following the same deployment model proven with Mitsubishi, GE Steam Power, and Siemens Energy. This creates operational stickiness because integrating a dedicated qualified facility into a primary supply chain carries huge switching costs, providing exceptional multiyear revenue and volume visibility. Transcripts +1
Contracts with GE Vernova extend over 5-6 years on average, with specific delivery schedules agreed at the part number level. This is a dramatic shift from the company's historical customer mix, where revenue was more dependent on shorter-term orders and less integrated supply chains. The dedicated facility model creates structural revenue visibility that simply didn't exist before. But this visibility comes with its own set of challenges. Transcripts
The 5-6 year order visibility from GE Vernova has significant implications for working capital management. Currently, working capital days (inventory plus receivables) are elevated at approximately 200 days in H1 FY27, with a target to improve to 160-180 days in H2 FY27. The company has made upfront investments in inventory as plants are at different levels of capacity ramp-up, which is expected to normalize. From FY27 onwards, this strategic inventory buildup should convert to revenues, easing cash flows. Transcripts +1
The company has also accumulated approximately ₹100 crores in GST credits over the past two years, expected to be realized by H1 FY28, supporting future cash flow and liquidity. This working capital efficiency improvement is critical because it directly impacts cash flow conversion. The extended order visibility enables capacity planning and investment decisions with high confidence, allowing the company to optimize working capital deployment and improve cash flow conversion efficiency over time. Transcripts +1
While GE Vernova provides the foundation, the defense opportunity represents a transformative strategic milestone.
The engine is currently under testing, with the next phase going on the weapon platform within 4-6 weeks from the Q1 FY27 earnings call. Transcripts +3
This positions Azad as a fully integrated propulsion systems player, moving up the value chain from traditional component supplier to primary technology integration partner. The company has been advised to prepare for massive production once certification is completed, with the total timeline to production readiness appearing to be approximately 3-4 months from initial delivery. Currently, the Aerospace & Defense segment contributes 16.8% of revenue with 24.7% YoY growth, but this could expand significantly as the turbojet engine moves from testing to mass production. Transcripts +6
Azad is building 8 dedicated manufacturing units at its Tunikibollaram plant, with 4 facilities successfully commissioned: Mitsubishi Heavy Industries, GE Power Systems, Siemens Energy, and Baker Hughes (inaugurated in April 2026). Civil construction across the remaining units is on track to wrap up within FY27, with commissioning targeted for completion by the balance of FY27. Each plant at full capacity is poised to generate approximately ₹150-180 crores, translating to potential revenue of roughly ₹1,200 crores from the newer plant. Transcripts +3
The company is beginning to see the "true power of structural operating leverage" as its assets move through the planned stabilization curve. Q1 FY27 standalone EBITDA margin stood at 37.6%, up 150 bps YoY from 36.1% and 90 bps sequentially from 36.7%. Yet management maintains a conservative guidance range of 32-35% for calculation and planning purposes. This gap between actual performance and guidance reflects the execution uncertainty that still exists. Transcripts +3
Return on Capital Employed tells the story of a company in transition. Reported ROCE has declined from 18.8% in FY24 to 9.2% in FY26, reflecting significant capital deployment during this transition year as facilities were commissioned ahead of revenue realization. Even adjusted ROCE (excluding capital work-in-progress) has declined from 20.7% in FY25 to 15.3% in FY26. InvestorPresentations +4
This pattern is expected to repeat with future expansion phases. Management expects stable operating levels by FY27 and maximum utilization to begin by FY28. Historical adjusted ROCE peaked at 28.3% in FY22 and maintained 20%+ levels during periods of optimal capacity utilization. The next leg of growth capex for visibility beyond FY30 will likely follow a similar pattern: temporary ROCE compression followed by recovery as utilization improves. Transcripts +1
The brokerage's historical projections show revenue CAGR of 33% for FY25-28E, significantly exceeding management guidance. This gap reflects confidence in the ₹6,500 crore order book with 5-6 year visibility, faster capacity utilization than management assumes, and potential from the GTRE/DRDO turbojet engine program. Transcripts
The current valuation metrics are staggering: P/E ratio of 135.15x, P/B ratio of 12.31x, and market cap of approximately ₹19,150 crore. The market has moved ahead of the brokerage's 5-6 year order visibility thesis, pricing in not just visibility but execution certainty. At these valuations, the stock has limited margin for error.
Several factors could trigger significant multiple compression from current levels. Throughput conversion shortfalls are the most critical risk.
Stabilization is not immediate—each plant is at a different stage of qualification. If facilities take 12-18 months versus the expected 6-9 months to reach optimal utilization, the P/E could compress to 80-90x as growth timelines extend. Transcripts +1
Working capital normalization delays represent another significant risk. If working capital days remain above 200 days through FY27 or if bill discounting fails to reduce debtor days to the 90-day target, cash flow concerns could trigger sharp derating. Margin sustainability is equally critical. If EBITDA margins decline to the 32-35% guidance range versus the current 37.6%, earnings downgrades would directly impact stock price. Transcripts
One factor working in Azad's favor is INR depreciation. The company has significant export exposure at approximately 94-95% of total revenue, with contracts primarily dollar-denominated. Rupee depreciation can provide a revenue boost of approximately 5-6%, though management considers this a secondary factor rather than a primary growth lever. Material cost is not very high, so rupee depreciation doesn't significantly impact costs on the import side. Transcripts +2
The company employs a multi-layered hedging approach. The primary hedge comes from natural offsetting—94-95% export revenues provide natural hedging against currency fluctuations. Foreign currency loans create natural hedges against export receivables, and bill discounting lines provide forward currency protection the moment sales are booked. The target is to have entire export exposure hedged through bill discounting facilities by Q4 FY27. Transcripts +2
Azad Engineering's story is compelling but not without risk. The GE Vernova integration provides structural revenue visibility that reduces volatility compared to the historical customer mix. The defense breakthrough creates a new growth engine that could meaningfully diversify revenue over time. The facility commissioning is progressing, and margins are expanding despite the capacity ramp-up.
But the current valuation leaves little room for execution missteps. The market is pricing in perfect execution with minimal delays in facility stabilization, 33%+ revenue CAGR sustained through FY29, 37-38% margin sustainability despite capacity ramp-up, and working capital normalization within 6-9 months. Any deviation from this bullish narrative could trigger significant multiple compression, potentially 30-50% from current levels if multiple triggers materialize simultaneously.
For investors, the key metrics to watch in the coming quarters are working capital days progress toward the 160-180 target, facility utilization rates across commissioned plants, margin sustainability as new capacity comes online, and defense certification progress. The story remains intact, but the risk-reward balance has shifted considerably after the 111% six-month rally.
